Boehringer Ingelheim Settles US Pradaxa Litigation For $650 MillionForbesBoehringer Ingelheim said today that it will pay $650 million in a “comprehensive settlement” of lawsuits over Pradaxa (dabigatran), the company’s novel anticoagulant. The company said that it expects the settlement will resolve about 4,000 current cases …Boehringer Pays $650 Million to End Blood Thinner CasesBloombergBoehringer to settle lawsuits against blockbuster drug for $650 millionYahoo Healthall 12 news articles …Read Full Story
Boehringer Ingelheim Settles US Pradaxa Litigation For $650 Million - Forbes
Real Estate of Cebu
